Healthcare Global Enterprises Limited — PPTs, 05-02-2026: Investor Presentation

**Business Performance:** HealthCare Global Enterprises (HCG) delivered robust Q3 performance, with revenue up 13% YoY to 633.1 Cr, fueled by 8% volume growth and a 5% rise in Average Revenue Per Patient (ARPP, excluding fertility). For the nine-month period (9MFY26), revenue increased 15% YoY to 1,893.1 Cr. Growth was broad-based across all clusters, notably West (+17%), South (+9%), East (+13%), and International operations (+42%).

**Growth Drivers or Strategy:** HCG's strategy focuses on optimizing its existing network through talent acquisition and international business expansion. It's also investing in growth via brownfield expansions and entering new markets, while improving efficiency and patient experience with advanced technology and digital initiatives.

**Recent Developments:** The company has completed significant senior leadership augmentations. A key project, the new North Bangalore Greenfield Hospital, which will feature MR-LINAC technology, is expected to commence operations by the end of Q4FY26.

**Key Financial Metrics:** Adjusted EBITDA for Q3 surged 20% YoY to 110.8 Cr, with margins expanding to 17.5%. For 9MFY26, Adjusted EBITDA grew 20% YoY to 345.8 Cr, achieving an 18.3% margin. Return on Capital Employed (ROCE) pre-tax for 9MFY26 stood stable at 13.3%.

**Management Commentary / Outlook:** Management highlighted their commitment to redefining comprehensive cancer care through a patient-centric approach, superior technology, and clinical excellence. The North Bangalore hospital is poised to set new benchmarks in the field.